The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer

Expert Opinion on Drug Safety
José Mª Mazarico GallegoLuis Paz-Ares

Abstract

Introduction: Lung cancer is the leading cancer-related cause of death worldwide. The introduction of immune checkpoint inhibitors (ICIs) for the treatment of lung cancer has significantly improved the outcome of these patients. Pembrolizumab, a monoclonal IgG4-kappa antibody against programmed-death-1 (PD-1) protein, nowadays represents a standard of care for NSCLC patients. Although it has a favorable toxicity profile, some immune-related adverse events (irAEs) can be life-threatening, therefore its knowledge may help to optimize the care of these patients.Areas covered: The authors review data regarding the efficacy and safety of pembrolizumab from the most relevant clinical trials as well as toxicities reported in the clinical use. Special considerations of use in special populations will be noted. Finally, its toxicity profile will be compared with other ICIs used in NSCLC.Expert opinion: In the scenario of NSCLC, pembrolizumab shows a favorable safety profile with less than 10% serious immune-related adverse events (irAEs) when used in monotherapy and without adding relevant extra-toxicity to chemotherapy when used in combination. Monotherapy with pembrolizumab is associated with better health-related quality of life than...Continue Reading

References

Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jan 22, 2014·Nature Reviews. Clinical Oncology·Tara C Gangadhar, Robert H Vonderheide
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 20, 2015·Journal for Immunotherapy of Cancer·Leila KhojaAnthony M Joshua
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Nov 26, 2015·Nature Structural & Molecular Biology·Giovanna ScapinCorey Strickland
Dec 19, 2015·Cancer Cell·Lorenzo GalluzziGuido Kroemer
Oct 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MenziesG V Long
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 26, 2016·Journal for Immunotherapy of Cancer·Bridgette A KanzDouglas B Johnson
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Feb 6, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Katherine L MarchRyan E Owens
Feb 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R HuiN A Rizvi
Mar 23, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MalvezziE Negri
Apr 22, 2017·The Journal of Infectious Diseases·Cynthia L GayUNKNOWN AIDS Clinical Trials 5326 Study Team
Jul 19, 2017·Journal of Immunotherapy·Adam S KittaiMatthew Taylor
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 14, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Gabriele CapursoPaolo Giorgio Arcidiacono
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
May 1, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mathieu LesouhaitierRoch Houot
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Aug 25, 2018·American Journal of Respiratory and Critical Care Medicine·Paul T ElkingtonChristian H Ottensmeier
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Ravindran KanesvaranRonald Maggiore
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Oct 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardUNKNOWN ESMO Guidelines Committee
Dec 7, 2018·American Journal of Botany·Haley A Branch, Rowan F Sage
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer

❮ Previous
Next ❯

Citations

Aug 25, 2020·The British Journal of Ophthalmology·Blake Hugo FortesLauren A Dalvin
Aug 6, 2021·Therapeutic Advances in Medical Oncology·Jiadi GanLi Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Australian Prescriber
Expert Opinion on Drug Safety
Juan Martin-LiberalJames Larkin
Expert Opinion on Biological Therapy
Kiichiro Ninomiya, Katsuyuki Hotta
© 2021 Meta ULC. All rights reserved